Umbas R - Search Results

1

Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer.

Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, Schaafsma HE, Debruyne FM, Isaacs WB. Umbas R, et al. Cancer Res. 1992 Sep 15;52(18):5104-9. Cancer Res. 1992. PMID: 1516067

2

Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer.

Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA. Umbas R, et al. Cancer Res. 1994 Jul 15;54(14):3929-33. Cancer Res. 1994. PMID: 7518346

3

Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization.

Tamimi Y, van der Poel HG, Denyn MM, Umbas R, Karthaus HF, Debruyne FM, Schalken JA. Tamimi Y, et al. Among authors: umbas r. Cancer Res. 1993 Nov 15;53(22):5512-6. Cancer Res. 1993. PMID: 8221692

4

Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors.

Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM, Schalken JA. Bringuier PP, et al. Among authors: umbas r. Cancer Res. 1993 Jul 15;53(14):3241-5. Cancer Res. 1993. PMID: 8324734

5

Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer.

Umbas R, Isaacs WB, Bringuier PP, Xue Y, Debruyne FM, Schalken JA. Umbas R, et al. Int J Cancer. 1997 Aug 22;74(4):374-7. doi: 10.1002/(sici)1097-0215(19970822)74:4<374::aid-ijc2>3.0.co;2-s. Int J Cancer. 1997. PMID: 9291424

6

Mechanisms associated with abnormal E-cadherin immunoreactivity in human bladder tumors.

Bringuier PP, Giroldi LA, Umbas R, Shimazui T, Schalken JA. Bringuier PP, et al. Among authors: umbas r. Int J Cancer. 1999 Nov 26;83(5):591-5. doi: 10.1002/(sici)1097-0215(19991126)83:5<591::aid-ijc3>3.0.co;2-6. Int J Cancer. 1999. PMID: 10521791

7

Expression of markers for transitional cell carcinoma in normal bladder mucosa of patients with bladder cancer.

Witjes JA, Umbas R, Debruyne FM, Schalken JA. Witjes JA, et al. Among authors: umbas r. J Urol. 1995 Dec;154(6):2185-9. J Urol. 1995. PMID: 7500486

8

Changes in keratin expression during the development of benign prostatic hyperplasia.

Xue Y, Smedts F, Umbas R, Aalders TW, Debruyne FM, de la Rosette JJ, Schalken JA. Xue Y, et al. Among authors: umbas r. Eur Urol. 1997;32(3):332-8. Eur Urol. 1997. PMID: 9358223

9

Expression of periglandular tenascin-C and basement membrane laminin in normal prostate, benign prostatic hyperplasia and prostate carcinoma.

Xue Y, Li J, Latijnhouwers MA, Smedts F, Umbas R, Aalders TW, Debruyne FM, De La Rosette JJ, Schalken JA. Xue Y, et al. Among authors: umbas r. Br J Urol. 1998 Jun;81(6):844-51. doi: 10.1046/j.1464-410x.1998.00659.x. Br J Urol. 1998. PMID: 9666769

10

The importance of targeting intracrinology in prostate cancer management.

Hamid ARAH, Tendi W, Sesari SS, Mochtar CA, Umbas R, Verhaegh G, Schalken JA. Hamid ARAH, et al. Among authors: umbas r. World J Urol. 2019 May;37(5):751-757. doi: 10.1007/s00345-018-2529-7. Epub 2018 Oct 22. World J Urol. 2019. PMID: 30350016 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

68 results

Search Page

Filters